mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-31. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
An advocacy group that has taken a position against research on newborn blood screening data without parental consent is the Citizens' Council for Health Freedom, who take the position that newborn health screening for "a specific set of newborn genetic conditions" is a very different matter than storing the data or those DNA samples indefinitely to "use them for genetic research without parental knowledge or consent."
=== Pregnancy and breastfeeding === It has not been determined of Cetacaine has any adverse defects on the formation of the fetus or if it is transferred through breastfeeding. It is recommended that professional advise should be taken in these regards.
In 2015, about a million gunshot wounds occurred from interpersonal violence. Firearms, globally in 2016, resulted in 251,000 deaths up from 209,000 in 1990. Of these deaths 161,000 (64%) were the result of assault, 67,500 (27%) were the result of suicide, and 23,000 were accidents. Firearm related deaths are most common in males between the ages of 20 and 24 years. In 2016, the countries with the largest number of deaths from firearms are Brazil, United States, Mexico, Colombia, Venezuela, Guatemala, Bahamas and South Africa which make up just over half the total. In the United States in 2015, about half of the 44,000 people who died by suicide did so with a gun. As of 2016, the countries with the highest rates of gun violence per capita were El Salvador, Venezuela, and Guatemala with 40.3, 34.8, and 26.8 violent gun deaths per 100,000 people respectively. The countries with the lowest rates of were Singapore, Japan, and South Korea with 0.03, 0.04, and 0.05 violent gun deaths per 100,000 people respectively.
Sources: en.wikipedia.org
Taruc Hukbalahap Monument at Garden of Peace Memorial Park in Santa Monica, San Luis, Pampanga, was unveiled to honor about 400 guerrilla fighters (including Luis Taruc, the late Antonio Sumang and 96-year-old Praxedes Clarin, in the statue, one of the nine surviving Huks) including Olimpia Ingal, Narciso Garcia, Josefa Tolentino, and Clemente Miranda, all 94, Dominga Sanchez, Anastacia Sali, and Natalia Lacanlale, all 98 and Francisca Salas, 99).
2.A.1 Major Facilitator superfamily (MFS), see also Lactose permease, Phosphate permease and Glucose transporter 2.A.2 The Glycoside-Pentoside-Hexuronide (GPH):Cation Symporter Family 2.A.3 The Amino Acid-Polyamine-Organocation (APC) Family 2.A.4 Cation diffusion facilitator (CDF) Family 2.A.5 Zinc (Zn2+)-Iron (Fe2+) Permease Family 2.A.6 Resistance-Nodulation-Cell Division Superfamily, see also SecDF protein-export membrane protein 2.A.7 The Drug/Metabolite Transporter (DMT) Superfamily 2.A.8 The Gluconate:H+ Symporter (GntP) Family 2.A.9 The Membrane Protein Insertase (YidC/Alb3/Oxa1) Family 2.A.10 The 2-Keto-3-Deoxygluconate Transporter (KdgT) Family 2.A.11 The Citrate-Mg2+:H+ (CitM) Citrate-Ca2+:H+ (CitH) Symporter (CitMHS) Family 2.A.12 ATP:ADP Antiporter Family 2.A.13 The C4-Dicarboxylate Uptake (Dcu) Family 2.A.14 Lactate Permease Family 2.A.15 The Betaine/Carnitine/Choline Transporter (BCCT) Family 2.A.16 Tellurite-resistance/Dicarboxylate Transporter Family 2.A.17 Proton-dependent Oligopeptide Transporter Family 2.A.18 The Amino Acid/Auxin Permease (AAAP) Family 2.A.19 The Ca2+:Cation Antiporter (CaCA) Family 2.A.20 The Inorganic Phosphate Transporter (PiT) Family 2.A.21 Solute:Sodium Symporter Family 2.A.22 The Neurotransmitter:Sodium Symporter Family 2.A.23 The Dicarboxylate/Amino Acid:Cation (Na+ or H+) Symporter (DAACS) Family 2.A.24 The 2-Hydroxycarboxylate Transporter (2-HCT) Family 2.A.25 Alanine or Glycine:Cation Symporter (AGCS) Family 2.A.26 The Branched Chain Amino Acid:Cation Symporter (LIVCS) Family 2.A.27 The Glutamate:Na+ Symporter (ESS) Family 2.A.28 Bile Acid:Na+ Symporter Family 2.A.29 Mitochondrial carrier Family 2.A.30 Cation-Chloride Cotransporter (CCC) Family 2.A.31 Anion Exchanger Family 2.A.32 The Silicon Transporter (Sit) Family 2.A.33 NhaA Na+:H+ Antiporter (NhaA) Family 2.A.34 The NhaB Na+:H+ Antiporter (NhaB) Family 2.A.35 The NhaC Na+:H+ Antiporter (NhaC) Family 2.A.36 Monovalent Cation:Proton Antiporter-1 (CPA1) Family 2.A.37 Monovalent Cation:Proton Antiporter-2 (CPA2) Family 2.A.38 K+ Transporter (Trk) Family 2.A.39 Nucleobase:Cation Symporter-1 (NCS1) Family 2.A.40 Nucleobase:Cation Symporter-2 (NCS2) Family 2.A.41 The Concentrative Nucleoside Transporter (CNT) Family 2.A.42 The Hydroxy/Aromatic Amino Acid Permease (HAAAP) Family 2.A.43 The Lysosomal Cystine Transporter (LCT) Family 2.A.45 Arsenite-Antimonite Efflux Family 2.A.46 The Benzoate:H+ Symporter (BenE) Family 2.A.47 Divalent Anion:Na+ Symporter (DASS) Family 2.A.48 The Reduced Folate Carrier (RFC) Family 2.A.49 Chloride Carrier/Channel (ClC) Family 2.A.50 The Glycerol Uptake (GUP) Family 2.A.51 The Chromate Ion Transporter (CHR) Family 2.A.52 The Ni2+-Co2+ Transporter (NiCoT) Family 2.A.53 Sulfate permease (SulP) Family 2.A.54 The Mitochondrial Tricarboxylate Carrier (MTC) Family 2.A.55 The Metal Ion (Mn2+-iron) Transporter (Nramp) Family 2.A.56 The Tripartite ATP-independent Periplasmic Transporter (TRAP-T) Family 2.A.57 The Equilibrative Nucleoside Transporter (ENT) Family 2.A.58 The Phosphate:Na+ Symporter (PNaS) Family 2.A.59 The Arsenical Resistance-3 (ACR3) Family 2.A.60 Organo Anion Transporter (OAT) Family 2.A.61 The C4-dicarboxylate Uptake C (DcuC) Family 2.A.62 The NhaD Na+:H+ Antiporter (NhaD) Family 2.A.63 The Monovalent Cation (K+ or Na+):Proton Antiporter-3 (CPA3) Family 2.A.64 Twin Arginine Targeting (Tat) Family 2.A.65 The Bilirubin Transporter (BRT) Family 2.A.66 The Multidrug/Oligosaccharidyl-lipid/Polysaccharide (MOP) Flippase Superfamily 2.A.67 The Oligopeptide Transporter (OPT) Family 2.A.68 The p-Aminobenzoyl-glutamate Transporter (AbgT) Family 2.A.69 The Auxin Efflux Carrier (AEC) Family 2.A.70 The Malonate:Na+ Symporter (MSS) Family 2.A.71 The Folate-Biopterin Transporter (FBT) Family 2.A.72 The K+ Uptake Permease (KUP) Family 2.A.73 The Short Chain Fatty Acid Uptake (AtoE) Family 2.A.74 The 4 TMS Multidrug Endosomal Transporter (MET) Family 2.A.75 The L-Lysine Exporter (LysE) Family 2.A.76 The Resistance to Homoserine/Threonine (RhtB) Family 2.A.77 The Cadmium Resistance (CadD) Family 2.A.78 The Branched Chain Amino Acid Exporter (LIV-E) Family 2.A.79 The Threonine/Serine Exporter (ThrE) Family 2.A.80 The Tricarboxylate Transporter (TTT) Family 2.A.81 The Aspartate:Alanine Exchanger (AAEx) Family 2.A.82 The Organic Solute Transporter (OST) Family 2.A.83 The Na+-dependent Bicarbonate Transporter (SBT) Family 2.A.84 The Chloroplast Maltose Exporter (MEX) Family 2.A.85 The Aromatic Acid Exporter (ArAE) Family 2.A.86 The Autoinducer-2 Exporter (AI-2E) Family (Formerly the PerM Family, TC #9.B.22) 2.A.87 The Prokaryotic Riboflavin Transporter (P-RFT) Family 2.A.88 Vitamin Uptake Transporter (VUT or ECF) Family 2.A.89 The Vacuolar Iron Transporter (VIT) Family 2.A.90 Vitamin A Receptor/Transporter (STRA6) Family 2.A.91 Mitochondrial tRNA Import Complex (M-RIC) (Formerly 9.C.8) 2.A.92 The Choline Transporter-like (CTL) Family 2.A.94 The Phosphate Permease (Pho1) Family 2.A.95 The 6TMS Neutral Amino Acid Transporter (NAAT) Family 2.A.96 The Acetate Uptake Transporter (AceTr) Family 2.A.97 The Mitochondrial Inner Membrane K+/H+ and Ca2+/H+ Exchanger (LetM1) Family 2.A.98 The Putative Sulfate Exporter (PSE) Family 2.A.99 The 6TMS Ni2+ uptake transporter (HupE-UreJ) Family 2.A.100 The Ferroportin (Fpn) Family 2.A.101 The Malonate Uptake (MatC) Family (Formerly UIT1) 2.A.102 The 4-Toluene Sulfonate Uptake Permease (TSUP) Family 2.A.103 The Bacterial Murein Precursor Exporter (MPE) Family 2.A.104 The L-Alanine Exporter (AlaE) Family 2.A.105 The Mitochondrial Pyruvate Carrier (MPC) Family 2.A.106 The Ca2+:H+ Antiporter-2 (CaCA2) Family 2.A.107 The MntP Mn2+ Exporter (MntP) Family 2.A.108 The Iron/Lead Transporter (ILT) Family 2.A.109 The Tellurium Ion Resistance (TerC) Family 2.A.110 The Heme Transporter, heme-responsive gene protein (HRG) Family 2.A.111 The Na+/H+ Antiporter-E (NhaE) Family 2.A.112 The KX Blood-group Antigen (KXA) Family 2.A.113 The Nickel/cobalt Transporter (NicO) Family 2.A.114 The Putative Peptide Transporter Carbon Starvation CstA (CstA) Family 2.A.115 The Novobiocin Exporter (NbcE) Family 2.A.116 The Peptidoglycolipid Addressing Protein (GAP) Family 2.A.117 The Chlorhexadine Exporter (CHX) family 2.A.118 The Basic Amino Acid Antiporter (ArcD) Family 2.A.119 The Organo-Arsenical Exporter (ArsP) Family 2.A.120 The Putative Amino Acid Permease (PAAP) Family 2.A.121 The Sulfate Transporter (CysZ) Family 2.A.122 The LrgB/CidB holin-like auxiliary protein (LrgB/CidB) Family 2.A.123 The Sweet; PQ-loop; Saliva; MtN3 (Sweet) Family 2.A.124 The Lysine Exporter (LysO) Family 2.A.125 The Eukaryotic Riboflavin Transporter (E-RFT) Family 2.A.126 The Fatty Acid Exporter (FAX) Family 2.A.127 Enterobacterial Cardiolipin Transporter (CLT) Family
== Issue == Archduchess Sophie of Austria (5 March 1855 – 29 May 1857). Archduchess Gisela of Austria (12 July 1856 – 27 July 1932). Married Prince Leopold of Bavaria (second cousin) in 1873. They had four children. Rudolf, Crown Prince of Austria (21 August 1858 – 30 January 1889). Married Princess Stephanie of Belgium in 1881. They had one daughter. He died in a murder–suicide. Archduchess Marie Valerie of Austria (22 April 1868 – 6 September 1924). Married Archduke Franz Salvator (second cousin) in 1890. They had ten children.
Sources: en.wikipedia.org
The Pakistan Institute of Fashion and Design, commonly referred to as PIFD, (formerly known as Pakistan School of Fashion Design) is a design institute specialising in design education. It offers a four-year course of study leading to a bachelor's degree.
=== Dental implants === The most common use of bone grafting is in the application of dental implants to restore the edentulous area of a missing tooth. Dental implants require bones underneath them for support and proper integration into the mouth. As mentioned earlier bone grafts come in various forms such as autologous (from the same person), Allograft, Xenograft (mainly bovine bone), and Alloplastic materials. Bone grafts can be used prior to implant placement or simultaneously. People who have been edentulous (without teeth) for a prolonged period may not have enough bone left in the necessary locations. In this case, autologous bone can be taken from the chin, from the pilot holes for the implants, or even from the iliac crest of the pelvis and inserted into the mouth underneath the new implant. Alternatively, exogenous bone can be used: xenograft is the most commonly used, because it offers the advantage of exceptional volume stability over time. Allograft offers the best regeneration quality but has lower volume stability. Often a mix of different kinds of bone grafts is used. In general, bone graft is either used en bloc (such as from the chin or the ascending ramus area of the lower jaw) or particulated, in order to be able to adapt it better to a defect. Dental bone grafting is a specialized oral surgical procedure that has been developed to reestablish lost jawbone. This loss can be a result of dental infection of abscess, periodontal disease, trauma, or the natural process of aging.
Some courtroom observers during the first trial described Letby as "aloof and indifferent" and noted her frequent claims of having no recollection of events, which they felt contributed to an impression of guilt.
=== No development reported === AB-101 (RJ-101) – topical – alopecia – undefined mechanism of action BRM-421 (GPN-00136, PDSP) – topical – alopecia – cell proliferation stimulant Dimethylcurcumin (ASC-J9, AJ-101) – topical – male pattern baldness – androgen receptor degradation enhancer Lepzacitinib (ATI-1777) – topical – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor PF-277343 – unspecified – alopecia – undefined mechanism of action Research programme: janus kinase inhibitors - Aclaris Therapeutics/ JAKPharm – unknown – alopecia areata – Janus kinase 3 inhibitors Research programme: skin diseases therapeutics - Quark Pharmaceuticals (QP-AL1; QP-AL2) – unknown – alopecia (chemotherapy-induced) – RNA interference Research programme: stem cell therapeutics - Histostem (Cirrhosis HMScs) – unknown – alopecia – cell replacement Synephrine (AB-102) – topical – alopecia – α1-adrenergic receptor agonist Valproic acid (VPA spray) – topical – male pattern baldness – glycogen synthase kinase 3β inhibitor, Wnt signalling pathway stimulant
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.